Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Neurochem
2017 Jan 01;1401:37-52. doi: 10.1111/jnc.13883.
Show Gene links
Show Anatomy links
Therapeutic concentrations of varenicline in the presence of nicotine increase action potential firing in human adrenal chromaffin cells.
Hone AJ
,
Michael McIntosh J
,
Rueda-Ruzafa L
,
Passas J
,
de Castro-Guerín C
,
Blázquez J
,
González-Enguita C
,
Albillos A
.
???displayArticle.abstract???
Varenicline is a nicotinic acetylcholine receptor (nAChR) agonist used to treat nicotine addiction, but a live debate persists concerning its mechanism of action in reducing nicotine consumption. Although initially reported as α4β2 selective, varenicline was subsequently shown to activate other nAChR subtypes implicated in nicotine addiction including α3β4. However, it remains unclear whether activation of α3β4 nAChRs by therapeutically relevant concentrations of varenicline is sufficient to affect the behavior of cells that express this subtype. We used patch-clamp electrophysiology to assess the effects of varenicline on native α3β4* nAChRs (asterisk denotes the possible presence of other subunits) expressed in human adrenal chromaffin cells and compared its effects to those of nicotine. Varenicline and nicotine activated α3β4* nAChRs with EC50 values of 1.8 (1.2-2.7) μM and 19.4 (11.1-33.9) μM, respectively. Stimulation of adrenal chromaffin cells with 10 ms pulses of 300 μM acetylcholine (ACh) in current-clamp mode evoked sodium channel-dependent action potentials (APs). Under these conditions, perfusion of 50 or 100 nM varenicline showed very little effect on AP firing compared to control conditions (ACh stimulation alone), but at higher concentrations (250 nM) varenicline increased the number of APs fired up to 436 ± 150%. These results demonstrate that therapeutic concentrations of varenicline are unlikely to alter AP firing in chromaffin cells. In contrast, nicotine showed no effect on AP firing at any of the concentrations tested (50, 100, 250, and 500 nM). However, perfusion of 50 nM nicotine simultaneously with 100 nM varenicline increased AP firing by 290 ± 104% indicating that exposure to varenicline and nicotine concurrently may alter cellular behavior such as excitability and neurotransmitter release.
Albuquerque,
Mammalian nicotinic acetylcholine receptors: from structure to function.
2009, Pubmed
Albuquerque,
Mammalian nicotinic acetylcholine receptors: from structure to function.
2009,
Pubmed
Antolin-Fontes,
The habenulo-interpeduncular pathway in nicotine aversion and withdrawal.
2015,
Pubmed
Arias,
Pharmacological and molecular studies on the interaction of varenicline with different nicotinic acetylcholine receptor subtypes. Potential mechanism underlying partial agonism at human α4β2 and α3β4 subtypes.
2015,
Pubmed
Azam,
α-Conotoxin BuIA[T5A;P6O]: a novel ligand that discriminates between α6ß4 and α6ß2 nicotinic acetylcholine receptors and blocks nicotine-stimulated norepinephrine release.
2010,
Pubmed
,
Xenbase
Azam,
Molecular interaction of α-conotoxin RgIA with the rat α9α10 nicotinic acetylcholine receptor.
2015,
Pubmed
Baker,
Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial.
2016,
Pubmed
Benowitz,
Nicotine chemistry, metabolism, kinetics and biomarkers.
2009,
Pubmed
Bordia,
Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.
2012,
Pubmed
Campling,
Acute activation, desensitization and smoldering activation of human acetylcholine receptors.
2013,
Pubmed
Capelli,
Stable expression and functional characterization of a human nicotinic acetylcholine receptor with α6β2 properties: discovery of selective antagonists.
2011,
Pubmed
Cartier,
A new alpha-conotoxin which targets alpha3beta2 nicotinic acetylcholine receptors.
1996,
Pubmed
,
Xenbase
Chavez-Noriega,
Characterization of the recombinant human neuronal nicotinic acetylcholine receptors alpha3beta2 and alpha4beta2 stably expressed in HEK293 cells.
2000,
Pubmed
Coe,
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
2005,
Pubmed
,
Xenbase
Dani,
Mesolimbic dopamine and habenulo-interpeduncular pathways in nicotine withdrawal.
2013,
Pubmed
David,
Biochemical and functional properties of distinct nicotinic acetylcholine receptors in the superior cervical ganglion of mice with targeted deletions of nAChR subunit genes.
2010,
Pubmed
,
Xenbase
Dwoskin,
Nicotinic receptor-based therapeutics and candidates for smoking cessation.
2009,
Pubmed
Elgoyhen,
Alpha 9: an acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells.
1994,
Pubmed
,
Xenbase
Faessel,
Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
2006,
Pubmed
George,
Function of human α3β4α5 nicotinic acetylcholine receptors is reduced by the α5(D398N) variant.
2012,
Pubmed
,
Xenbase
Gerzanich,
Homomers of alpha 8 and alpha 7 subunits of nicotinic receptors exhibit similar channel but contrasting binding site properties.
1994,
Pubmed
,
Xenbase
Gorsline,
Comparison of plasma nicotine concentrations after application of nicoderm (nicotine transdermal system) to different skin sites.
1992,
Pubmed
Gourlay,
Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine.
1997,
Pubmed
Grady,
Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release.
2009,
Pubmed
Harrison-Woolrych,
Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand.
2012,
Pubmed
Henningfield,
Higher levels of nicotine in arterial than in venous blood after cigarette smoking.
1993,
Pubmed
Hone,
Nicotinic acetylcholine receptors in dorsal root ganglion neurons include the α6β4* subtype.
2012,
Pubmed
Hone,
Positional scanning mutagenesis of α-conotoxin PeIA identifies critical residues that confer potency and selectivity for α6/α3β2β3 and α3β2 nicotinic acetylcholine receptors.
2013,
Pubmed
,
Xenbase
Hone,
A novel fluorescent alpha-conotoxin for the study of alpha7 nicotinic acetylcholine receptors.
2009,
Pubmed
,
Xenbase
Hone,
α-Conotoxins Identify the α3β4* Subtype as the Predominant Nicotinic Acetylcholine Receptor Expressed in Human Adrenal Chromaffin Cells.
2015,
Pubmed
,
Xenbase
Innocent,
Alpha-conotoxin Arenatus IB[V11L,V16D] [corrected] is a potent and selective antagonist at rat and human native alpha7 nicotinic acetylcholine receptors.
2008,
Pubmed
,
Xenbase
Jackson,
The α3β4* nicotinic acetylcholine receptor subtype mediates nicotine reward and physical nicotine withdrawal signs independently of the α5 subunit in the mouse.
2013,
Pubmed
Jensen,
Pharmacological characterisation of α6β4⁎ nicotinic acetylcholine receptors assembled from three chimeric α6/α3 subunits in tsA201 cells.
2014,
Pubmed
Kikkawa,
Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers.
2011,
Pubmed
Koegelenberg,
Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial.
2014,
Pubmed
Lotfipour,
A single administration of low-dose varenicline saturates α4β2* nicotinic acetylcholine receptors in the human brain.
2012,
Pubmed
Luo,
Characterization of a novel α-conotoxin TxID from Conus textile that potently blocks rat α3β4 nicotinic acetylcholine receptors.
2013,
Pubmed
,
Xenbase
Mao,
Heterogeneity of nicotinic cholinergic receptors in rat superior cervical and nodose Ganglia.
2006,
Pubmed
Mihalak,
Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.
2006,
Pubmed
,
Xenbase
Papke,
Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.
2011,
Pubmed
,
Xenbase
Poth,
Heterogeneity of nicotinic receptor class and subunit mRNA expression among individual parasympathetic neurons from rat intracardiac ganglia.
1997,
Pubmed
Pérez-Alvarez,
Key role of the nicotinic receptor in neurotransmitter exocytosis in human chromaffin cells.
2007,
Pubmed
Ravva,
Population pharmacokinetic analysis of varenicline in adult smokers.
2009,
Pubmed
Rollema,
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
2007,
Pubmed
Rollema,
Functional interactions of varenicline and nicotine with nAChR subtypes implicated in cardiovascular control.
2014,
Pubmed
,
Xenbase
Rollema,
Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
2010,
Pubmed
,
Xenbase
Scholze,
Subunit composition of α5-containing nicotinic receptors in the rodent habenula.
2012,
Pubmed
Shih,
Differential expression and function of nicotinic acetylcholine receptors in subdivisions of medial habenula.
2014,
Pubmed
Singh,
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.
2011,
Pubmed
Slimak,
Habenular expression of rare missense variants of the β4 nicotinic receptor subunit alters nicotine consumption.
2014,
Pubmed
Sobue,
Effect of application sites and multiple doses on nicotine pharmacokinetics in healthy male Japanese smokers following application of the transdermal nicotine patch.
2005,
Pubmed
Stauderman,
Characterization of human recombinant neuronal nicotinic acetylcholine receptor subunit combinations alpha2beta4, alpha3beta4 and alpha4beta4 stably expressed in HEK293 cells.
1998,
Pubmed
Stokes,
Use of an α3β4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties.
2012,
Pubmed
,
Xenbase
Tammimäki,
Impact of human D398N single nucleotide polymorphism on intracellular calcium response mediated by α3β4α5 nicotinic acetylcholine receptors.
2012,
Pubmed
Wang,
Assembly of human neuronal nicotinic receptor alpha5 subunits with alpha3, beta2, and beta4 subunits.
1996,
Pubmed
,
Xenbase
Whiteaker,
Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist.
2007,
Pubmed
,
Xenbase
Zhou,
Pharmacological properties of nicotinic acetylcholine receptors expressed by guinea pig small intestinal myenteric neurons.
2002,
Pubmed
